AI stocks are rallying — but this precision-medicine leader just surged 51% as its cancer diagnostics story heats up.
The company is Guardant Health, ticker GH, and it has quietly turned into one of the hottest names in the precision-medicine space. Shares are up more than 51% in just the past month, as investors suddenly wake up to how big its role could be in the future of cancer detection and genomic diagnostics.
Guardant isn’t a flashy biotech chasing speculative drug trials — it’s building the infrastructure for blood-based cancer testing, one of the most transformative technologies in modern healthcare. Its liquid biopsy platforms are rapidly becoming essential tools for oncologists, hospitals, and pharmaceutical companies.
In its latest quarter, Guardant delivered surprisingly strong revenue growth, driven by surging demand for Guardant360, its flagship tumor-profiling test, and Reveal, its minimal residual disease platform. Test volumes hit new highs, biopharma partnerships expanded, and payer coverage continues to broaden — all signaling accelerating adoption across the entire oncology ecosystem.
But the real excitement is coming from the company’s early-cancer-detection program, considered one of the biggest commercial opportunities in diagnostics. Guardant recently released promising clinical updates showing strong screening performance and confirmed plans to scale commercialization. This puts GH in direct competition with the largest players in the space — and Wall Street is starting to pay attention.
Analysts have begun raising price targets, citing improving margins, a clearer path toward profitability, and Guardant’s growing moat in genomic testing. Management also highlighted meaningful cost controls and operating-leverage tailwinds as test volumes continue to rise.
With early detection gaining widespread momentum, reimbursement expanding quickly, and oncology shifting toward precision-based screening, Guardant Health may be one of the most under-the-radar growth stories heading into 2026 — and the recent 51% surge might only be the beginning.
We send stocks like this all the time inside our Crown Elite Research Service.
You get access to real trade setups before they move with —
full breakdowns
ideal buy levels
stop loss levels
price targets
weekly watchlists and reports
and more..
Sign up before November 24 and you’ll also get my Top 5 Elite Stocks for November 2025 list.
After the 24th, the bonus is gone.
Talk soon,
— Jordan
👑 Crown Trading